Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium

On February 7, 2019 Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, reported that it will present a poster at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in San Francisco (Press release, Arvinas, FEB 7, 2019, View Source [SID1234533163]). The presentation will highlight the company’s lead product candidate, ARV-110, an oral androgen receptor (AR)-targeted PROTAC (Proteolysis-Targeting Chimera) protein degrader for the treatment of men with metastatic castration-resistant prostate cancer. ARV-110 employs Arvinas’ proprietary PROTAC protein degradation technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Abstract Number: 259
Poster: L16
Session Information: Poster Session A: Prostate Cancer
Session Date/Time: February 14; 11:30 a.m. – 1:00 p.m.; 5:30 – 6:30 p.m.
All abstracts for the Symposium will be released by ASCO (Free ASCO Whitepaper) on February 11, 2019 at 5:00 p.m. EST on meetinglibrary.asco.org.

About ARV-110
ARV-110 is an orally-bioavailable PROTAC protein degrader designed to selectively target and degrade androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). ARV-110 has demonstrated promising activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. Arvinas believes the differentiated pharmacology of ARV-110, including its iterative activity, has the potential to translate into improved clinical outcomes for patients.